NEW YORK (GenomeWeb) – WaferGen Bio-systems announced that its shares have regained compliance for listing on the Nasdaq.

On Dec. 13, the Fremont, California-based firm received a letter from the market's Listing Qualifications Department acknowledging that the closing bid price of its common stock had been $1.00 or more for ten consecutive business days as of Dec. 12.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.